Pharminent

AbbVie files for FDA approval of etentamig in multiple myeloma

AbbVie has filed for FDA approval of etentamig, a BCMAxCD3 bispecific antibody, in multiple myeloma.

FDA details quicker approval pathway for personalized gene therapies

The FDA issued new details on a faster approval pathway for personalized gene therapies, using an “individualized feature space” approach. Rare disease advocates welcomed the move.

Arrowhead wins UK marketing authorization for Redemplo in FCS

Arrowhead Pharmaceuticals received marketing authorization from the UK MHRA for Redemplo as an adjunct to diet to reduce triglyceride levels in adults with familial chylomicronemia syndrome.

FDA grants orphan drug status to Octant’s OCT-980 for retinitis pigmentosa

The FDA granted orphan drug designation to Octant’s OCT-980, an investigational oral small molecule, for the treatment of retinitis pigmentosa.

Lilly says retatrutide beat Novo’s Ozempic in diabetes study

Lilly reported that its “triple-G” drug retatrutide outperformed Novo’s Ozempic in a diabetes study.

Ferring to acquire fertility startup Gameto for up to $1.38B

Switzerland’s Ferring Pharmaceuticals agreed to acquire US fertility startup Gameto for up to $1.38 billion, gaining rights to a technology intended to simplify the in vitro fertilization process.

Teva acquires BXCL501 for $57.5M upfront from BioXcel

Teva acquired BXCL501 from BioXcel for $57.5 million upfront, and Rumi Therapeutics entered an option agreement with Enthorin for a PDE2 inhibitor for Fragile X.

Artiva to end autoimmune cell therapy work and cut staff

Artiva Biotherapeutics said it will discontinue its autoimmune cell therapy work and cut staff after patient deaths and a data shortfall, attributing one fatality to a drug used to prepare patients for cell therapy rather than to the cell therapy itself.